Lubbock Digestive Disease Associates Research Institute

Lubbock Digestive Disease Associates Research Institute, a division of GI Alliance, brings the future of gastroenterology medicine to Adults and Pediatrics in the Arlington Heights, Gurnee, and Glenview areas. We strive to provide all patients, current and new, with access to cutting edge treatments prior to them being granted FDA approved.

For new treatments and therapies to receive FDA approval, the investigational product must pass through four different phases: Phase 1, Phase 2 and Phase 3, are pre-FDA approval, while Phase 4 is considered post-FDA approval. ADH Research Institute participates in all four Phases, 1 through 4, with our primary focus in Phase 2 and Phase 3 of the clinical research testing phase.

Our current treatment options include but are not limited to the following conditions: Crohn’s Disease, Ulcerative Colitis, Celiac Disease, Clostridium Difficile or C. Diff, and Eosinophilic Esophagitis or EoE.